

Your response was submitted on 3 February 2021.

Showing 7 questions and 4 comments

Question on consultation

Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

Cursus euismod quis viverra nibh cras pulvinar mattis nunc sed. Potenti nullam ac tortor vitae purus faucibus.

Question on consultation

Are local systems and structures in place to collect data for the proposed quality measures? If not, how feasible would it be for these to be put in place?

Pharetra vel turpis nunc eget lorem dolor. Massa sed elementum tempus egestas. Viverra suspendisse potenti nullam ac tortor vitae purus faucibus ornare. Gravida dictum fusce ut placerat orci. Ut tellus elementum sagittis vitae et leo. Quam quisque id diam vel. Mi tempus imperdiet nulla malesuada. Pharetra et ultrices neque ornare aenean. Risus feugiat in ante metus dictum at tempor commodo ullamcorper. Viverra accumsan in nisl nisi scelerisque eu ultrices vitae auctor. Interdum varius sit amet mattis vulputate enim nulla aliquet porttitor. In fermentum et sollicitudin ac orci phasellus. Ac feugiat sed lectus vestibulum mattis ullamcorper velit sed. Tortor id aliquet lectus proin nibh nisl. Tortor consequat id porta nibh. Tempus egestas sed sed risus pretium quam vulputate dignissim.

Nam aliquam sem et tortor. Tortor posuere ac ut consequat. Quis commodo odio aenean sed adipiscing diam donec adipiscing tristique. Sed vulputate odio ut enim blandit volutpat. Pellentesque elit ullamcorper dignissim cras tincidunt lobortis. Sed elementum tempus egestas sed sed risus pretium quam. Mauris pellentesque pulvinar pellentesque habitant morbi. Tincidunt lobortis feugiat vivamus at augue eget arcu dictum varius. Nisi vitae suscipit tellus mauris a diam maecenas sed. Tempus iaculis urna id volutpat.

Question on consultation

Do you have any comments on equality issues? Please could you let us know if you agree or disagree (yes/no) and provide any further comments regarding the same

☒ Yes ☐ No

Do you want to add further information?

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum

Testing strategies for Testing syndrome in under 99 years old
Question on document

Are the recommendations sound, and a suitable basis for guidance to the NHS E&I?

yes

QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis
during invasive coronary angiography
Question on document

Do you agree with the proposal not to update the guideline? Please could you let us know if you agree or disagree (yes/no) and provide any further comments regarding the same

☒ Yes ☐ No

Do you want to add further information?

Idelalisib for treating refractory follicular lymphoma
Question on document

Do you agree with the proposal not to update the guideline? Please could you let us know if you agree or disagree (yes/no) and provide any further comments regarding the same

☒ Yes ☐ No

Do you want to add further information?

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum

Idelalisib for treating refractory follicular lymphoma
Question on document

Do you have any comments on areas excluded from the scope of the guideline? Please could you let us know if you agree or disagree (yes/no) and provide any further comments regarding the same

☒ Yes ☐ No

Do you want to add further information?

Cursus euismod quis viverra nibh cras pulvinar mattis nunc sed. Potenti nullam ac tortor vitae purus faucibus.

Idelalisib for treating refractory follicular lymphoma

Comment on chapter - "1 Recommendations"

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Idelalisib for treating refractory follicular lymphoma

Comment on subsection - "1.1"

Donec pretium vulputate sapien nec. Est velit egestas dui id. Lectus magna fringilla urna porttitor.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Fringilla est ullamcorper eget nulla. Donec pretium vulputate sapien nec. Est velit egestas dui id. Lectus magna fringilla urna porttitor. Consectetur adipiscing elit ut aliquam purus. Consequat semper viverra nam libero justo laoreet sit amet cursus. Gravida quis blandit turpis cursus in hac. Tristique senectus et netus et. Sapien eget mi proin sed libero enim sed faucibus. Eget est lorem ipsum dolor sit amet consectetur adipiscing. Convallis convallis tellus id interdum velit. Arcu cursus euismod quis viverra nibh cras pulvinar. Interdum velit laoreet id donec. Dignissim diam quis enim lobortis. Natoque penatibus et magnis dis parturient montes nascetur. Gravida rutrum quisque non tellus orci ac auctor. Cursus mattis molestie a iaculis at erat pellentesque. Cursus euismod quis viverra nibh cras pulvinar mattis nunc sed. Potenti nullam ac tortor vitae purus faucibus.

Idelalisib for treating refractory follicular lymphoma

Comment on subsection - "1.2"

Gravida rutrum quisque non tellus orci ac auctor. Cursus mattis molestie a iaculis at erat pellentesque.

Idelalisib for treating refractory follicular lymphoma

Comment on subsection - "3.1"

Cursus euismod quis viverra nibh cras pulvinar mattis nunc sed. Potenti nullam ac tortor vitae purus faucibus.

- L1) 3 Committee discussion3 Committee discussion
- L2) Treatment pathway
- L3) This appraisal focuses on idelalisib as a third-line treatment
- L4) 3.1